Alopecia Universalis After Alemtuzumab Treatment for Multiple Sclerosis: A Two-Year Follow-Up of Two Patients

    Giovanna Borriello, Antonio Ianniello, Ahmed Toosy
    Image of study
    TLDR Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.
    Two female patients in their thirties developed Alopecia Universalis (AU), a condition characterized by complete loss of scalp and body hair, 12 months after their second cycle of Alemtuzumab treatment for Multiple Sclerosis (MS). This treatment is known to cause secondary autoimmunity in up to 40% of patients. One patient's AU was associated with a significant drop in vitamin D levels, while the other experienced joint swelling; both had thyroid alterations and neither showed hair regrowth after 2 years. These cases highlight AU as a potential secondary autoimmune manifestation of Alemtuzumab, underscoring the importance of patient screening and monitoring for predisposing factors to secondary autoimmunity.
    Discuss this study in the Community →

    Cited in this study

    2 / 2 results

    Related

    5 / 5 results